Skip to main content

Indianapolis Biomarker Cancer Dx Firm Reels in $6.3M in Series A Funding

NEW YORK (GenomeWeb News) – Indianapolis-based company CS-Keys has gained nearly $6.3 million in Series A financing from previous and new investors, the company said today.
 
The cash infusion will fund the company’s initial product offering, the caPCNA Key Stain, a stain used to help pathologists detect the occurrence and re-occurrence of several types of cancer, including colorectal, breast, prostate, and ovarian cancers.
 
The financing round included investments from Triathlon Medical Ventures, which seeded the company, Clarian Health Ventures, Prolog Ventures, Ceres Venture Fund, and Spring Mill Venture Partners.
 
The company also is developing other biomarker-based diagnostics, including the caPCNA Elisa and caPCNA Cytology products.
 
 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.